Haleon plc
HLN
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $42.3B
$9.60
▼ -2.64%
P/E
—
Mkt Cap
$42.3B
52-Wk Range
$8.65–$11.28
52-Week Range
$8.65 - $11.28
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 1.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.2).
- Premium valuation to sector peers
Growth
Stable outlook
Value
Premium valuation to sector peers
Momentum
Strong
+8.0% over 3m
Quality
Excellent
Solid business
Dividend
Solid
2.13% yield
Smart-money signal
Who's buying HLN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
JUL 30, 2026
Reported EPS of $0.23 vs $0.27 consensus (-13.9% surprise). Revenue of $7.5B vs $7.4B expected (+1.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-13.9%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: Jefferies · Aug 24, 2026
vs Industry
How HLN stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.